Cancer Cachexia Market Report by Therapeutics, Mode of Action, Distribution Channel, and Region 2024-2032
세계 암 악액질 시장 규모는 2023년 21억 달러에 달했습니다. 향후 IMARC Group은 2032년까지 시장이 2024년부터 2032년까지 4.1%의 연평균 성장률(CAGR)로 30억 달러에 달할 것으로 예측했습니다.
암 악액질은 다인성, 숙주-식균성, 소모성 증후군을 말하며, 조직 염증, 비자발적 제지방 체중 감소, 음의 단백질 균형, 식욕 부진, 근육 위축이 특징입니다. 결핵, 다발성 경화증, 만성폐쇄성폐질환(COPD), 인체면역결핍바이러스(HIV) 등 다양한 만성질환의 발병으로 인해 발생합니다. 암 악액질은 황체호르몬, 코르티코스테로이드, 병용요법 등 다양한 치료제를 이용해 치료할 수 있습니다. 이 중 황체 호르몬은 식욕을 개선하고 체중 증가를 촉진하는 합성 또는 천연 스테로이드 호르몬이며, 코르티코 스테로이드는 염증을 완화하고 과도한 면역 체계를 억제하는 데 도움이 됩니다.
암 악액질 시장 동향:
암과 악액질 유병률의 증가, 특히 노령 인구의 증가로 인해 첨단 치료법과 약물에 대한 수요가 증가하고 있으며, 이는 주로 시장 성장을 촉진하고 있습니다. 이는 암 악액질을 치료할 수 있는 새로운 치료제의 가용성에 대한 소비자의 인식이 높아짐에 따라 더욱 뒷받침되고 있습니다. 또한, 약물 요법, 비약물 요법 및 임상시험을 통해 제지방 체중(LBM)을 개선하기 위한 병용 요법에 대한 환자들의 성향이 또 다른 성장 촉진요인으로 작용하고 있습니다. 이와 함께 메게스트롤 아세테이트, 덱사메타손, 메틸프레드니솔론과 같은 식욕촉진제가 소화 개선을 위해 널리 사용되고 있는 것도 시장 성장에 기여하고 있습니다. 또한, 암 악액질 치료를 위한 효과적인 의약품의 시장 개척에 초점을 맞춘 괄목할 만한 기술 발전이 시장 성장을 더욱 촉진하고 있습니다. 이와는 별도로, 암 악액질의 원인과 증상 및 첨단 치료법 사용의 이점에 대해 사람들을 교육하기 위해 여러 국가의 정부 기관 및 비정부기구(NGO)가 시행하고 있는 여러 가지 유리한 이니셔티브가 시장에 대한 긍정적인 전망을 창출하고 있습니다.
본 보고서에서 다루는 주요 질문
- 2023년 세계 암 악액질 시장 규모는?
- 2024-2032년 세계 암 악액질 시장의 예상 성장률은?
- 세계 암 악액질 시장을 이끄는 주요 요인은 무엇인가?
- COVID-19가 세계 암 악액질 시장에 미치는 영향은?
- 치료제를 기반으로 한 세계 암 악액질 시장의 분석은?
- 작용기전에 따른 세계 암 악액질 시장의 분류는?
- 세계 암 악액질 시장의 주요 지역은?
- 세계 암 악액질 시장의 주요 플레이어/기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 암 악액질 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 치료제별
제7장 시장 내역 : 작용기서별
제8장 시장 내역 : 유통 채널별
제9장 시장 내역 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
- 개요
- 구매자의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 참여업체의 위협
- 대체품의 위협
제13장 가격 분석
제14장 경쟁 상황
- 시장 구조
- 주요 기업
- 주요 기업 개요
- AAVogen Inc.
- Actimed Therapeutics Ltd.
- Aphios Corporation
- Artelo Biosciences Inc.
- AVEO Pharmaceuticals Inc.
- Fresenius Kabi AG(Fresenius SE & Co. KGaA)
- Helsinn Healthcare SA
- Merck & Co. Inc.
- NGM Biopharmaceuticals Inc.
- Pfizer Inc.
- Tetra Bio-Pharma
ksm
The global cancer cachexia market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.0 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032.
Cancer cachexia refers to a multifactorial, host-phagocytic, wasting syndrome that is characterized by systematic inflammation, involuntary loss of lean body mass, negative protein balance, loss of appetite and muscle atrophy. It is caused due to the occurrence of various chronic diseases, including tuberculosis (TB), multiple sclerosis, chronic obstructive pulmonary disease (COPD) and human immunodeficiency virus (HIV). Cancer cachexia can be treated with the utilization of various therapeutics, such as progestogen, corticosteroid, and combination therapy. Amongst these, a progestogen is a synthetic or natural steroid hormone that improves appetite and promotes weight gain, whereas corticosteroid assists in mitigating inflammation and suppressing overactive immune systems.
Cancer Cachexia Market Trends:
The increasing prevalence of cancer and cachexia, especially amongst the rising geriatric populations, is facilitating the demand for advanced therapeutic treatment and drugs, which in turn, is primarily driving the market growth. This is further supported by the increasing awareness amongst consumers regarding the availability of novel therapeutic drugs to treat cancer cachexia. Additionally, the shifting inclination of patients toward combinational therapies for improving lean body mass (LBM) through pharmacological, non-pharmacological therapies and clinical trials is acting as another growth-inducing factor. In line with this, the extensive utilization of several appetite stimulants, such as megestrol acetate, dexamethasone, and methylprednisolone, for improving digestion is also contributing to the market growth. Moreover, significant technological advancements that are emphasizing on the development of effective medicines for cancer cachexia treatment are further propelling the market growth. Apart from this, the numerous favorable initiatives being undertaken by the government bodies of various countries and non-governmental organizations (NGOs) for sensitizing people regarding the causes of cancer cachexia, their symptoms and benefits of using advanced treatments are creating a positive outlook for the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer cachexia market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on therapeutics, mode of action and distribution channel.
Breakup by Therapeutics:
Progestogens
Corticosteroids
Combination Therapy
Others
Breakup by Mode of Action:
Appetite Stimulators
Weight Loss Stabilizers
Breakup by Distribution Channel:
Hospital Stores
Retail Pharmacy
Online Pharmacy
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Artelo Biosciences Inc., AVEO Pharmaceuticals Inc., Fresenius Kabi AG (Fresenius SE & Co. KGaA), Helsinn Healthcare SA, Merck & Co. Inc., NGM Biopharmaceuticals Inc., Pfizer Inc. and Tetra Bio-Pharma.
Key Questions Answered in This Report
- 1. What was the size of the global cancer cachexia market in 2023?
- 2. What is the expected growth rate of the global cancer cachexia market during 2024-2032?
- 3. What are the key factors driving the global cancer cachexia market?
- 4. What has been the impact of COVID-19 on the global cancer cachexia market?
- 5. What is the breakup of the global cancer cachexia market based on the therapeutics?
- 6. What is the breakup of the global cancer cachexia market based on the mode of action?
- 7. What are the key regions in the global cancer cachexia market?
- 8. Who are the key players/companies in the global cancer cachexia market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Cancer Cachexia Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Therapeutics
- 6.1 Progestogens
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Corticosteroids
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Combination Therapy
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Mode of Action
- 7.1 Appetite Stimulators
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Weight Loss Stabilizers
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Hospital Stores
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Retail Pharmacy
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Online Pharmacy
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 AAVogen Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.2 Actimed Therapeutics Ltd.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 Aphios Corporation
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 Artelo Biosciences Inc.
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.5 AVEO Pharmaceuticals Inc.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 Fresenius Kabi AG (Fresenius SE & Co. KGaA)
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 SWOT Analysis
- 14.3.7 Helsinn Healthcare SA
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Merck & Co. Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 NGM Biopharmaceuticals Inc.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.10 Pfizer Inc.
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Tetra Bio-Pharma
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
